Trial Search Results

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.

The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment of chronic heart failure due to LV systolic dysfunction.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Mesoblast, Inc.

Stanford Investigator(s):


  • Biological: Allogeneic Mesenchymal Precursor Cells (MPC)
  • Other: Sham Comparator


Phase 3


Inclusion Criteria:

   - The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.

   - The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at
   least 6 months

   - The patient is on stable, optimally tolerated dosages of HF therapies including
   beta-blockers (approved for country-specific usage), angiotensin-converting enzyme
   (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone
   antagonists, without change in dose for at least 1 month before study intervention

   - The patient is on a stable, outpatient, oral diuretic dosing regimen in which the
   patient remains clinically stable during screening.

   - Other Criteria apply, please contact the investigator

Exclusion Criteria:

   - The patient has NYHA Functional Class I or Functional Class IV symptoms.

   - Other Criteria apply, please contact the investigator

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305